Opinion|Videos|July 17, 2024
SEQUOIA Arm D Study: Zanubrutinib plus Venetoclax in Treatment-Naive CLL/SLL with del(17p) and/or TP53 Mutations
Author(s)Mazyar Shadman, MD, MPH
A blood cancer specialist discusses the latest data from the SEQUOIA Arm D trial investigating zanubrutinib plus venetoclax in treatment-naïve patients with CLL and del(17p) and/or TP53 mutations.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- Please briefly discuss the latest results from the SEQUOIA Arm D trial, evaluating zanubrutinib plus venetoclax in treatment-naïve patients with CLL and del(17p) and/or TP53 mutations.
- How does the efficacy of zanubrutinib + venetoclax compare to SOCs in high-risk patients with del(17p) and/or TP53 mutations in CLL/SLL?
- How does the efficacy of zanubrutinib + venetoclax compare to SOCs in high-risk patients with del(17p) and/or TP53 mutations in CLL/SLL?
Newsletter
Stay up to date on practice-changing data in community practice.
SubscribeAdvertisement
Related to this article
FDA expands pirtobrutinib into first-line CLL/SLL for adults without 17p deletion, delivering major PFS gains versus bendamustine-rituximab.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Breakthrough Status to Multi-Cancer Early Detection Blood Test
2
FDA Clears Phase 2 Trial of B7-H3 CAR T MT027 for Brain Metastases
3
As New TGCT Therapies Advance, Route, Duration, and Coverage Shape CSF1R Inhibitor Choice
4
Alpha-Emitting RYZ101 Meets Phase 3 PFS End Point in Advanced GEP-NETs
5